menu
    • menu

    Find Niraparib Tosylate manufacturers, exporters & distributors on PharmaCompass

    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    17

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    1

    NDC API

    NDC API

    0

    VMF

    NDC API

    16

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 13,685

    MARKET PLACE

    2

    API

    2

    FDF

    3INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    18

    FDF Dossiers

    FDF Dossiers

    4

    FDA Orange Book

    FDA (Orange Book)

    6

    Europe

    Europe

    0

    Canada

    Canada

    8

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    55DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    35

    US Patents

    3

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    113

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    2,614

    Finished Drug Prices

    Listed Dossiers

    41 RELATED EXCIPIENT COMPANIES

    64EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 1038915-73-9, Mk-4827 tosylate, Mk-4827 (tosylate), Mk-4827-tosylate, Niraparib (tosylate), Mk 4827 tosylate
    Molecular Formula
    C26H28N4O4S
    Molecular Weight
    492.6  g/mol
    InChI Key
    LCPFHXWLJMNKNC-PFEQFJNWSA-N
    FDA UNII
    75KE12AY9U
    Niraparib Tosylate
    1 2D Structure

    Niraparib Tosylate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-methylbenzenesulfonic acid;2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
    2.1.2 InChI
    InChI=1S/C19H20N4O.C7H8O3S/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10)/t14-;/m1./s1
    2.1.3 InChI Key
    LCPFHXWLJMNKNC-PFEQFJNWSA-N
    2.1.4 Canonical SMILES
    CC1=CC=C(C=C1)S(=O)(=O)O.C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
    2.1.5 Isomeric SMILES
    CC1=CC=C(C=C1)S(=O)(=O)O.C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
    2.2 Other Identifiers
    2.2.1 UNII
    75KE12AY9U
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1038915-73-9

    2. Mk-4827 Tosylate

    3. Mk-4827 (tosylate)

    4. Mk-4827-tosylate

    5. Niraparib (tosylate)

    6. Mk 4827 Tosylate

    7. Niraparib (mk-4827) Tosylate

    8. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-methylbenzenesulfonate

    9. 75ke12ay9u

    10. Mk-4827(niraparib) Tosylate

    11. 2h-indazole-7-carboxamide, 2-(4-(3s)-3-piperidinylphenyl)-, 4-methylbenzenesulfonate (1:1)

    12. Unii-75ke12ay9u

    13. Niraparib Tosylate Monohyrate

    14. Niraparib(mk-4827) Tosylate

    15. Schembl20522624

    16. Dtxsid801026487

    17. Hy-10619b

    18. Mfcd28167748

    19. S7625

    20. Ccg-269634

    21. Niraparib Tosylate [orange Book]

    22. Ac-30383

    23. As-56981

    24. A11848

    25. A909268

    26. Q27266392

    27. (3s)-3-[4-[7-(aminocarbonyl)-2h-indazol-2-yl]phenyl]piperidine Tosylate

    28. (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide 4-?methylbenzenesulfona?te

    29. 4-methylbenzenesulfonic Acid;2-[4-[(3s)-piperidin-3-yl]phenyl]indazole-7-carboxamide

    30. 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; 4-methylbenzene-1-sulfonic Acid

    2.4 Create Date
    2014-10-10
    3 Chemical and Physical Properties
    Molecular Weight 492.6 g/mol
    Molecular Formula C26H28N4O4S
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count4
    Exact Mass492.18312656 g/mol
    Monoisotopic Mass492.18312656 g/mol
    Topological Polar Surface Area136 Ų
    Heavy Atom Count35
    Formal Charge0
    Complexity655
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameZEJULA
    Active IngredientNIRAPARIB TOSYLATE
    CompanyTESARO INC (Application Number: N208447. Patents: 8071623, 8436185)

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696962600,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF","customerCountry":"SLOVENIA","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"15000","totalValueFC":"13925.4","currency":"EUR","unitRateINR":1287777.7777777778,"date":"11-Oct-2023","totalValueINR":"1159000","totalValueInUsd":"13925.4","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"4549647","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696962600,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF","customerCountry":"SLOVENIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"15000","totalValueFC":"77544.8","currency":"EUR","unitRateINR":1290800,"date":"11-Oct-2023","totalValueINR":"6454000","totalValueInUsd":"77544.8","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"4549709","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707849000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"TO THE ORDER OF.,","customerCountry":"SLOVENIA","quantity":"2.30","actualQuantity":"2.3","unit":"KGS","unitRateFc":"8000","totalValueFC":"18154.3","currency":"USD","unitRateINR":654927.3913043479,"date":"14-Feb-2024","totalValueINR":"1506333","totalValueInUsd":"18154.3","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"7531791","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715193000,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.09","actualQuantity":"0.09","unit":"KGS","unitRateFc":"30000","totalValueFC":"2617.1","currency":"USD","unitRateINR":2423826.555555556,"date":"09-May-2024","totalValueINR":"218144.39","totalValueInUsd":"2617.1","indian_port":"Hyderabad Air","hs_no":"29419090","bill_no":"9746080","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720549800,"product":"NIRAPARIB TOSYLATE MONOHYDRATE","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"CHANGZHOU PHARMACEUTICAL FACTORY","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"DR. REDDY\\'S LABORATORIES","customerCountry":"INDIA","quantity":"0.80","actualQuantity":"0.8","unit":"KGS","unitRateFc":"16500","totalValueFC":"13335.6","currency":"USD","unitRateINR":"1393425","date":"10-Jul-2024","totalValueINR":"1114740","totalValueInUsd":"13335.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4430180","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO.518, LAO DONG EAST ROAD, CHANGZHOU JIANGSU 213018, CHINA. Changzhou, , China China","customerAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE"}]
    11-Oct-2023
    10-Jul-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zentalis Pharmaceuticals Reports FDA Lifts Partial Clinical Hold on Azenosertib Studies

    Details:

    ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.


    Lead Product(s): Azenosertib,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: ZN-c3

    Study Phase: Phase I/ Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 16, 2024

    blank

    01

    Zentalis Pharmaceuticals

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Zentalis Pharmaceuticals

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Azenosertib,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zentalis Pharmaceuticals Reports FDA Lifts Partial Clinical Hold on Azenosertib Studies

    Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

    Brand Name : ZN-c3

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 16, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®

    Details:

    Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.


    Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area: Oncology Brand Name: Akeega

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: JANSSEN BIOTECH

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 01, 2024

    blank

    02

    Foundation Medicine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Foundation Medicine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : JANSSEN BIOTECH

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Approves FoundationOne®Liquid CDx as Companion Diagnostic for AKEEGA®

    Details : Akeega (niraparib, abiraterone acetate) is a tablet works by inhibiting approved for BRCA-mutated mCRPC in adults. The FDA has approved FoundationOne Liquid CDx as its companion diagnostic.

    Brand Name : Akeega

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 01, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

    Details:

    ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.


    Lead Product(s): Azenosertib,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: ZN-c3

    Study Phase: Phase I/ Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 18, 2024

    blank

    03

    Zentalis Pharmaceuticals

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Zentalis Pharmaceuticals

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Azenosertib,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

    Details : ZN-c3 (azenosertib), is a potentially first-in-class and best-in-class WEE1 inhibitor being investigated for advanced solid tumors and hematologic malignancies.

    Brand Name : ZN-c3

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Accepts GSK’s Priority Review for Expanded Jemperli Indication in Endometrial Cancer

    Details:

    Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


    Lead Product(s): Dostarlimab,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: Jemperli

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 24, 2024

    blank

    04

    GSK

    United Kingdom
    arrow
    SupplySide West 2024
    Not Confirmed

    GSK

    United Kingdom
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dostarlimab,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Accepts GSK’s Priority Review for Expanded Jemperli Indication in Endometrial Cancer

    Details : Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.

    Brand Name : Jemperli

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    April 24, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Positive RUBY Phase III Data Show Jemperli's Potential for Advanced Endometrial Cancer

    Details:

    Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


    Lead Product(s): Dostarlimab,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: Jemperli

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 16, 2024

    blank

    05

    GSK

    United Kingdom
    arrow
    SupplySide West 2024
    Not Confirmed

    GSK

    United Kingdom
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dostarlimab,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Positive RUBY Phase III Data Show Jemperli's Potential for Advanced Endometrial Cancer

    Details : Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.

    Brand Name : Jemperli

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    March 16, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Jemperli (dostarlimab) plus Zejula (niraparib) Combination Significantly Improved Progression-Free Survival in Primary Advanced or Recurrent Endometrial...

    Details:

    Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.


    Lead Product(s): Dostarlimab,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: Jemperli

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 18, 2023

    blank

    06

    GSK

    United Kingdom
    arrow
    SupplySide West 2024
    Not Confirmed

    GSK

    United Kingdom
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dostarlimab,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Jemperli (dostarlimab) plus Zejula (niraparib) Combination Significantly Improved Progression-Free...

    Details : Jemperli (dostarlimab) in combination with Zejula (niraparib) is being evaluated in phase 3 ciical trials for the treatment of primary advanced or recurrent endometrial cancer.

    Brand Name : Jemperli

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    December 18, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS in Patients with mCRPC with BRCA Alterations Treated w...

    Details:

    JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.


    Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area: Oncology Brand Name: JNJ-64091742

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 22, 2023

    blank

    07

    Johnson & Johnson

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Johnson & Johnson

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Final Multivariate Analysis from the Phase 3 MAGNITUDE Study Shows Trend Toward Improvement in OS ...

    Details : JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.

    Brand Name : JNJ-64091742

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 22, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)

    Details:

    GSK101 (IDE705), a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of PARP for the treatment of patients having tumors with BRCA or other homologous recombination mutations.


    Lead Product(s): IDE705,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: GSK101

    Study Phase: IND EnablingProduct Type: Small molecule

    Sponsor: GSK

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 21, 2023

    blank

    08

    Ideaya Biosciences

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Ideaya Biosciences

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : IDE705,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : GSK

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    IDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candi...

    Details : GSK101 (IDE705), a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of PARP for the treatment of patients having tumors with BRCA or other homologous recombination mutations.

    Brand Name : GSK101

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 21, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Janssen’s AKEEGA™ (niraparib and abiraterone aceta...

    Details:

    USFDA approves FoundationOne®CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate), the first-and-only dual action tablet, which was approved for deleterious BRCA-mutated metastatic castration-resistant prostate cancer in adults.


    Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area: Oncology Brand Name: Akeega

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 14, 2023

    blank

    09

    Johnson & Johnson Innovative Medicine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Johnson & Johnson Innovative Medicine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for ...

    Details : USFDA approves FoundationOne®CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate), the first-and-only dual action tablet, which was approved for deleterious BRCA-mutated metastatic castration-resistant prostate cancer ...

    Brand Name : Akeega

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 14, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-and-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive ...

    Details:

    KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.


    Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area: Oncology Brand Name: Akeega

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 11, 2023

    blank

    10

    Johnson & Johnson Innovative Medicine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed

    Johnson & Johnson Innovative Medicine

    U.S.A
    arrow
    SupplySide West 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Niraparib Tosylate,Abiraterone Acetate,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-and-Only Dual Action Ta...

    Details : KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.

    Brand Name : Akeega

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    August 11, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATES SUPPLIERS

    read-more
    read-more

    01

    Aarti Pharmalabs

    India
    CPhI India 2024
    Booth #2.F08
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    3-(Methoxy carbonyl)-2-nitrobenzoic acid

    CAS Number : 138229-59-1

    End Use API : Niraparib Tosylate

    About The Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, c...

    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Aarti Pharmalabs

    India
    CPhI India 2024
    Booth #2.F08
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    tert-butyl (3S)-3-(4-amino phenyl) piperidine-1-ca...

    CAS Number : 1171197-20-8

    End Use API : Niraparib Tosylate

    About The Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, c...

    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Sichuan Qingmu Pharmaceutical

    China
    SupplySide West 2024
    Not Confirmed
    arrow

    Sichuan Qingmu Pharmaceutical

    China
    SupplySide West 2024
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    (S)-3-(4-Bromophenyl)piperidine

    CAS Number : 1335523-82-4

    End Use API : Niraparib Tosylate

    About The Company : Sichuan Qingmu Pharmaceutical Co., Ltd, is a FDA approved cGMP factory in China, focusing on APIs’ production. The products are mainly Oncology APIs, Cardiova...

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Granulation

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search